MD Anderson led research in field, from small investigator-initiated studies to international confirmatory trials
MD Anderson News Release 09/26/2015
In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced, nonfunctional neuroendocrine tumors (NET) of the lung and gastrointestinal...
CheckMate-025 study led by The University of Texas MD Anderson Cancer Center portends paradigm change in standard of care treatment...
Protein-coding gene hnRNP K may be culprit in acute myeloid leukemia
MD Anderson News Release 09/24/2015
A protein-coding...
Football legend teams up with MD Anderson to support cancer research
MD Anderson News Release 09/22/2015
The University of Texas MD Anderson Cancer Center heads to San Antonio Oct. 13 for the sixth annual A Conversation With a Living Legend® honoring Pro Football Hall of Fame member and “Dancing with the Stars” champion Emmitt Smith.
The luncheon and program will be held at the Marriott Rivercenter, 101...
ACF Pharmaceuticals to explore the potential of novel, small molecule anti-cancer agents
MD Anderson News Release 09/15/2015
...
Cancer immunotherapy pioneer awarded prestigious U.S. medical research honor
MD Anderson News Release 09/08/2015
For inventing...
MD Anderson News Release 09/03/2015
Cellectis, the gene editing company employing proprietary technologies to develop best-in-class...
Free event offers information on the latest cancer treatment and prevention strategies
MD Anderson News Release 09/03/2015...
River Oaks Country Club event to pay tribute to Houston community
MD Anderson News Release 09/02/2015
The University...
Esteemed educator strives to ‘put the students first’
MD Anderson News Release 09/01/2015
Michelle Barton, Ph.D., professor...